Wang Tao,Liu Changrong,Deng Licai,et al.Clinical efficacies of different types of β receptor blockers for infantile hemangioma[J].Journal of Clinical Pediatric Surgery,,():168-172.[doi:10.3760/cma.j.cn101785-202208021-013]
Clinical efficacies of different types of β receptor blockers for infantile hemangioma
- Keywords:
- Hemangioma; Propranolol; Atenolol; Treatment Outcome; Drug-Related Side Effects and Adverse Reactions; Child Development
- Abstract:
- Objective To observe the clinical efficacy and complications of β receptor blockers for infantile hemangioma (IH) and observe the effect on growth and development during treatment.Methods From January 2017 to may 2022,33 IH children were recruited.They were randomized into two groups of propranolol (n=22) and atenolol (n=11) according to parental wishes.No significant inter-group differences existed in age,gender,location or type (P>0.05).The former group received an oral dose of non-selective propranolol 1.5-2 mg·kg-1·d-1.And the latter group was prescribed with atenolol at 0.5 mg·kg-1·d-1 in the first week and then 1 mg·kg-1·d-1.During monthly follow-ups,the changes of clinical manifestations such as tumor color,size,texture and the complications were recorded.Color Doppler ultrasound was performed for measuring tumor volume and evaluating growth and development.Results There was nostatistically significant difference in the age,gender,Location,and type of initial diagnosis between the two groups of chidren(P＞0.05).The effective rate of both groups was 100%.No statistically significant reduction occurred in tumor volume in neither groups at Month 1,5-6 and 10-12 post-treatment (P>0.05).Adverse reactions of drug dosing occurred in propranolol group (5/22,22.7%) with respiratory symptoms,fretting or sleep disorder and atenolol group(2/11,18.2%)with fretting or sleep disorder.No other serious adverse reactions occurred.No abnormality was found in physical development of neither groups during follow-ups.The developmental quotient of two groups did not differ significantly at Month 1/3/6/9 post-dosing (P>0.05).Conclusions The efficacies and complications of propranolol and atenolol are comparable for infantile hemangioma.No significant inter-group difference exists in growth and development during treatment.Regarding the impact of respiratory tract,atenolol may replace propranolol for infantile hemangiomas.
References:
[1] 中华医学会整形外科分会血管瘤和脉管畸形学组.血管瘤和脉管畸形的诊断及治疗指南(2019版)[J].组织工程与重建外科杂志,2019,15(5):277-317.DOI:10.3969/j.issn.1673-0364.2019.05.001.Group of Hemangioma & Vascular Deformities,Plastic Surgery Branch,Chinese Medical Association:CSSVA Guidelines for Vascular Anomalies (Edition 2019)[J].J Tissue Eng Reconstr Surg,2019,15(5):277-317.DOI:10.3969/j.issn.1673-0364.2019.05.001.
[2] 郑家伟,王绪凯,秦中平,等.口服普萘洛尔治疗婴幼儿血管瘤中国专家共识(2022版)[J].中国口腔颌面外科杂志,2022,20(4):313-319.DOI:10.19438/j.cjoms.2022.04.001.Zheng JW,Wang XK,Qin ZP,et al.Chinese Expert Consensus on Using Oral Propranolol for Infantile Hemangiomas (Edition 2022)[J].China J Oral Maxillofac Surg,2022,20(4):313-319.DOI:10.19438/j.cjoms.2022.04.001.
[3] Léauté-Labrèze C,Dumas de la Roque E,Hubiche T,et al.Propranolol for severe hemangiomas of infancy[J].N Engl J Med,2008,358(24):2649-2651.DOI:10.1056/NEJMc0708819.
[4] Rotter A,de Oliveira ZNP.Infantile hemangioma:pathogenesis and mechanisms of action of propranolol[J].J Dtsch Dermatol Ges,2017,15(12):1185-1190.DOI:10.1111/ddg.13365.
[5] Ji Y,Chen SY,Yang KY,et al.Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas:a randomized clinical trial[J].JAMA Otolaryngol Head Neck Surg,2021,147(7):599-607.DOI:10.1001/jamaoto.2021.0454.
[6] Xerfan EMS,Andersen ML,Facina AS,et al.Sleep disturbances as an adverse effect of propranolol use in children with infantile hemangioma[J].World J Pediatr,2020,16(5):537-538.DOI:10.1007/s12519-019-00335-2.
[7] Langley A,Pope E.Propranolol and central nervous system function:potential implications for paediatric patients with infantile haemangiomas[J].Br J Dermatol,2015,172(1):13-23.DOI:10.1111/bjd.13379.
[8] 邱桐,杨开颖,陈思源,等.普萘洛尔影响婴幼儿血管瘤患儿中枢神经系统功能的新进展[J].临床小儿外科杂志,2019,18(8):646-649.DOI:10.3969/j.issn.1671-6353.2019.08.006.Qiu T,Yang KY,Chen SY,et al.Potential effects of propranolol on central nervous system in children with infantile hemangioma[J].J Clin Ped Sur,2019,18(8):646-649.DOI:10.3969/j.issn.1671-6353.2019.08.006.
[9] Al-Rwebah H,Alkhodair R,Al-Khenaizan S.Propranolol-induced hyperkalemia in the management of infantile hemangioma[J].JAAD Case Rep,2020,6(4):359-361.DOI:10.1016/j.jdcr.2020.01.028.
[10] Rotter A,Samorano LP,de Oliveira Labinas GH,et al.Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol[J].Int J Dermatol,2017,56(2):190-194.DOI:10.1111/ijd.13442.
[11] Young ME,江帆,张子琛,等.投资儿童早期发展以及儿科医护工作者的作用[J].中华儿科杂志,2018,56(2):81-83.DOI:10.3760/cma.j.issn.0578-1310.2018.02.001.Young ME,Jiang F,Zhang ZC,et al.Investing in early childhood development and the role of pediatric medical workers[J].Chin J Pediatr,2018,56(2):81-83.DOI:10.3760/cma.j.issn.0578-1310.2018.02.001.
[12] Seebauer CT,Graus MS,Huang L,et al.Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma[J].J Clin Invest,2022,132(3):e151109.DOI:10.1172/JCI151109.
[13] Pandey V,Tiwari P,Imran M,et al.Adverse drug reactions following propranolol in infantile hemangioma[J].Indian Pediatr,2021,58(8):753-755.
[14] Wang Q,Xiang B,Chen SY,et al.Efficacy and safety of oral atenolol for the treatment of infantile haemangioma:a systematic review[J].Australas J Dermatol,2019,60(3):181-185.DOI:10.1111/ajd.12966.
[15] Gumina ME,Yan AC.Atenolol as an alternative to propranolol for the management of sleep disturbances in the treatment of infantile hemangiomas[J].Pediatr Dermatol,2019,36(4):556-557.DOI:10.1111/pde.13839.
[16] Laurens C,Abot A,Delarue A,et al.Central effects of beta-blockers may be due to nitric oxide and hydrogen peroxide release independently of their ability to cross the blood-brain barrier[J].Front Neurosci,2019,13:33.DOI:10.3389/fnins.2019.00033.
[17] 杨浩,舒强,郭晓东.婴幼儿血管瘤的治疗进展[J].临床小儿外科杂志,2019,18(8):640-645.DOI:10.3969/j.issn.1671-6353.2019.08.005.Yang H,Shu Q,Guo XD.Recent advances in the treatment of infantile hemangiomas[J].J Clin Ped Sur,2019,18(8):640-645.DOI:10.3969/j.issn.1671-6353.2019.08.005.
[18] Hu L,Zhou BR,Huang HZ,et al.Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas[J].J Dermatol,2016,43(10):1160-1166.DOI:10.1111/1346-8138.13324.
Memo
收稿日期:2022-8-11。
基金项目:福州市卫生健康科技计划项目(2019-S-wq20)
通讯作者:林向上,Email:66887151@qq.com